Prodrugs of Cysteamine – Dec 2006

Dr Roz Anderson, Professor Paul Groundwater and Mr Pratap Suryadevara, Sunderland Pharmacy School, University of Sunderland

Aims of the prodrug project

Although the vast range of research on gene therapy is encouraging, it is still a long way from offering a possible treatment, or even cure, for cystinosis. In the meantime, we are working on a strategy to improve the current treatment, cysteamine, using the prodrug approach. Our aims for cysteamine are to make it:

  • Palatable, with minimal taste and smell;
  • Rapidly and effectively absorbed from the gastrointestinal tract, with minimal disruption and damage to the stomach and duodenum;
  • Less susceptible to metabolism in the liver and excretion in the urine;
  • Directed to cells with accumulated lysosomal cystine.

By achieving these qualities, the unpleasant side effects will be decreased, while the bioavailability (the amount of drug actually available after ingestion, metabolism, excretion, and distribution around the body) will be increased. Usually, increased bioavailability results in the advantage of a decreased dose being required, which would further reduce the incidence of side effects and may allow fewer doses per day.

What is a prodrug and how could it help?

A prodrug is an inactive form of a known drug; it has no medicinal effect itself, but is activated in the body by a defined mechanism and breaks down to produce the active drug. By careful prodrug design, the active drug can be released in a particular location of the body or even over a desired timescale. There are a number of prodrugs already in clinical use; they overcome a range of problems associated with the therapeutic drug, such as poor absorption from the gastrointestinal tract (Pivampicillin is a prodrug of ampicillin, a poorly absorbed penicillin antibiotic) and rapid metabolism and excretion (Bambuterol is a prodrug of terbutaline, an anti-asthmatic drug that suffers from rapid metabolism and excretion when taken orally, which drastically reduces the available dose after ingestion), although some prodrugs are used to target the therapeutic drug to a particular location in the body (Levodopa is a prodrug of L-DOPA, a neurotransmitter that can be deficient in Parkinson’s Disease; this prodrug releases L-DOPA in the brain where it is required).

Cysteamine – the problems

Usually administered as its bitartrate salt, Cystagon┬«, cysteamine is pungent, tastes unpleasant and causes undesirable side effects after ingestion, such as nausea, vomiting, halitosis, body odour and stomach ulcers. The problems are exacerbated by the high and frequent dose required for effective treatment, which are also the most probable cause of other side effects noted recently. A considerable amount of the cysteamine dose is lost after absorption from the gastrointestinal tract through liver metabolism and excretion in the urine, such that the amount actually available after an oral dose is significantly lower than that ingested. Serum cysteamine continues to be metabolised after absorption, with a steady decline in cysteamine concentration to lower than the effective therapeutic concentration in about 6 – 8 hours.

Why is cysteamine currently the only effective treatment?

Cysteamine is unique in its ability to treat cystinosis effectively, most likely because it can counteract the clinical problems of cystinosis on several levels. First, there is the way in which cysteamine depletes the accumulated cystine from the lysosomes of cells. Cysteamine can enter cells and the lysosome relatively easily; once in the lysosome, it reacts with accumulated cystine to form a mixed disulfide. The disulfide is sufficiently similar in size (Figure 1A), shape and distribution of charge (Figure 1B) to the natural amino acid, lysine, that it can hijack the lysine transporter system, by which it leaves the lysosome.

Overlay of L-lysine

Figure 1A: Overlay of L-lysine with L-cysteine-cysteamine dimer showing the similarity in the shape, size and relative position of functional groups.

Comparison of surface charge distribution of L-lysine
Figure 1B: Comparison of surface charge distribution of L-lysine (left) with the disulfide, L-cysteine-cysteamine dimer (right). [Negatively charged regions shown in red; positively charged regions shown in blue; white represents neutral.]

Although there are a number of molecules that can enter the cell and lysosome and even react with cystine to form the mixed disulfide, the other candidates would not be able to hijack the lysine transporter, so would not have a defined route of excretion and may accumulate in the lysosome, eventually causing another clinical problem.

Secondly, cysteamine is a well-studied antioxidant, reacting with free radicals to inhibit their reaction with cell structures and minimising radical damage, such as that caused by irradiation. There is growing evidence that apoptosis (programmed cell death) is altered in cystinosis; this process is strongly linked to oxidative damage in cells and high concentrations of cellular oxidants can induce apoptosis through several pathways, including alteration of gene expression through modification of protein / DNA binding. There is a possibility that the antioxidant action of cysteamine contributes to its success in treating cystinosis.

With our current knowledge, we cannot improve on cysteamine; we can only improve its ability to reach and act upon the cells that most require its action.

The project at Sunderland

At Sunderland, Pratap Suryadevara’s PhD work is aimed at the design, synthesis and evaluation of a number of prodrugs of cysteamine. We designed the prodrugs to have little or no taste and smell, to cause minimum disruption to the membranes of the gastrointestinal tract, to be rapidly and effectively absorbed, to resist liver metabolism and the accompanying excretion, and to resist breakdown in the serum, but to be absorbed effectively into those cells with an active glutathione cycle, which includes kidney, liver, pancreas, and skin cells, amongst others. We believe that the glutathione cycle is intricately linked to the symptoms and clinical manifestation of cystinosis, if not to the progression of the disease itself, and believe that it is a valid ‘handle’ to target cysteamine to the affected cells.

We have synthesized 8 – 10 prodrug candidates and have developed a reliable and sensitive analytical technique to identify and quantify cysteamine in solution. We are currently evaluating the prodrugs for their ability to enter kidney cells and to release cysteamine intracellularly. The initial results are encouraging: the first prodrug candidate was effectively absorbed by the kidney cells and released cysteamine from the prodrug after internalisation.

Future Work

In collaboration with other researchers, we will quantify the reduction in taste and smell of the prodrugs in comparison to cysteamine using an electronic nose and electronic tongue.

The next stage of the work, in collaboration with Dr William Van’t Hoff, Great Ormond Street Hospital, will evaluate all of the prodrug candidates in normal human kidney and skin cells for their ability to be absorbed and release cysteamine intracellularly. They will then be tested for the same abilities against cystinotic kidney and skin cells; these experiments are important to ensure that the glutathione cycle remains active in cystinotic cells and that the absorption of prodrug and release of cysteamine are effective in these cells.

After these experiments, we will analyse and rationalise the data to choose the best prodrug candidates to go forward for further testing. Finally, the cystine depleting ability of the best candidates will be evaluated in collaboration with Dr Neil Dalton and his team at Guys Hospital, London.

We are in discussion with Orphan Europe on the development of the best prodrug candidates through pharmacokinetic and toxicological studies towards future clinical trials.

Comments are closed.

Novartis Gene Therapy Update We have received this message from Novartis regarding their gene therapy program for [...] Read more...
CNE International Conference 2024 Cystinosis Network Europe and Cystinosis Foundation UK are delighted to announce the 2024 [...] Read more...
Cystinosis Comic Book Series by Artist Kevin McCalla The Cystinosis Research Network in the US has teamed up with Kevin McCalla, a young artist who [...] Read more...
Summer 2023 Newsletter The Summer 2023 edition of our email newsletter is available to view at the link below. CFUK [...] Read more...
All website content copyright Cystinosis Foundation UK (Charity No.1074885) 1997-2013, except where explicitly stated.
Data Protection Act Registration Number: Z9880997. Please refer to our terms and conditions and our privacy policy.